December 20, 2018
Chugai Pharmaceutical said on December 19 that it has filed a new drug application in Japan for its ROS1/TRK inhibitor entrectinib for the treatment of NTRK fusion-positive solid tumors. Entrectinib has been granted designation for the sakigake fast-track pathway as...read more